- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00884949
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA
A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Birmingham, 영국
-
London, 영국
-
Manchester, 영국
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Documented history of reduced GALNS activity relative to the normal range of the laboratory performing the assay, or documented result of molecular genetic testing confirming diagnosis of MPS IVA.
- Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 16 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
- Between 5 and 18 years of age, inclusive.
- Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
- Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study.
- Willing to perform all study procedures as physically possible.
Exclusion Criteria:
- Previous hematopoietic stem cell transplant (HSCT).
- Has known hypersensitivity to BMN 110 or its excipients.
- Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
- Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
- Concurrent disease or condition that would interfere with study participation or safety, including, but not limited to, symptomatic cervical spine instability.
- Any condition that, in the view of the Principal Investigator (PI), places the subject at high risk of poor treatment compliance or of not completing the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: BMN 110
Within-patient Dose-Escalation
|
Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:
Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Subject Incidence of Treatment Emergent AEs
기간: Entire Study, through week 84
|
The primary objective of the study was to evaluate the safety of weekly infusions of BMN 110 administered in escalating doses to subjects with MPS IVA. The safety variable incidence of TEAE is summarized. |
Entire Study, through week 84
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in 6MWT
기간: Baseline to Weeks 12, 24, 36, 48, 72
|
Change from baseline in meters in 6-minute Walk Test.
As a measure of endurance, a 6-minute walk test (6MWT) was performed according to the American Thoracic Society Guidelines.
Patients were instructed to walk as far as possible in 6 minutes.
|
Baseline to Weeks 12, 24, 36, 48, 72
|
|
Change From Baseline in 3MSCT
기간: Baseline to Weeks 12, 24, 36, 48, 72
|
Change from baseline in the 3-minute Stair Climb Test.
Patients walked up stairs that have a railing, which could be used for support, for 3 minutes, with the number of stairs climbed recorded.
The test result was the number of steps climbed per minute.
|
Baseline to Weeks 12, 24, 36, 48, 72
|
|
Percent Change From Baseline in uKS
기간: Baseline to Weeks 12, 24, 36, 72
|
Percent Change from baseline in Normalized Urine KS.
The percent change was calculated (Week X value - baseline value)/baseline value *100%
|
Baseline to Weeks 12, 24, 36, 72
|
|
Percent Change From Baseline in MVV
기간: Baseline to Weeks 12, 24, 36, 72
|
Percent Change from baseline in Maximum Voluntary Ventilation.
|
Baseline to Weeks 12, 24, 36, 72
|
|
Percent Change From Baseline in FVC
기간: Baseline to Weeks 12, 24, 36, 72
|
Percent Change from baseline in Forced Vital Capacity.
|
Baseline to Weeks 12, 24, 36, 72
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Celeste Decker, MD, BioMarin Pharmceutical Inc.
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- MOR-002
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .